Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088192 · ClinicalTrials.gov registry record · NA
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
A NA study, sponsored by Eyetech Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
NCT00088192: Completed NA study, sponsored by Eyetech Pharmaceuticals.
NCT00088192 is a NA study that has completed, run by Eyetech Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088192, a NA study, has completed, sponsored by Eyetech Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
Interventions
- DRUG pegaptanib sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Phase | NA |
What the finished NCT00088192 record still lists
NCT00088192 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which pegaptanib sodium is the first listed.
NCT00088192 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088192 about?
NCT00088192 is a clinical study titled "Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)". To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabil...
What is the current status of trial NCT00088192?
This trial is currently completed. It is a NA study. The study started on 2004-07.
What interventions are being tested in trial NCT00088192?
The interventions under investigation include: pegaptanib sodium (DRUG).
Who is sponsoring clinical trial NCT00088192?
This trial is sponsored by Eyetech Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia